| 臺大學術典藏 |
2022-02-22T05:34:37Z |
Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: Role of viral infection
|
Tai D.-I.; CHIEN-HUNG CHEN; Chang T.-T.; Chen S.-C.; Liao L.-Y.; Kuo C.-H.; Chen Y.; Chen G.-H.; Yang S.-S.; Tang H.-S.; Lin H.H.; Lin D.-Y.; Lo S.K.; Du J.-M.; Lin K.-C.; Changchien C.-S.; Chang W.-Y.; Sheu J.-C.; Liaw Y.-F.; Chen D.-S.; Sung J.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:35Z |
Hepatitis B virus transmission and hepatocarcinogenesis: A 9 year retrospective cohort of 13 676 relatives with hepatocellular carcinoma
|
CHIEN-HUNG CHEN; Chen Y.Y.; Chen G.-H.; Yang S.-S.; Tang H.-S.; Lin H.H.; Lin D.-Y.; Lo S.K.; Du J.-M.; Chang T.-T.; Chen S.-C.; Liao L.-Y.; Kuo C.-H.; Lin K.-C.; Tai D.-I.; Changchien C.-S.; Chang W.-Y.; Sheu J.-C.; Chen D.-S.; Liaw Y.-F.; Sung J.-L. |
| 臺大學術典藏 |
2022-01-24T09:32:03Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
CHUN-JEN LIU; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:38Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
CHUN-JEN LIU; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-22T00:04:25Z |
Large stress-induced anisotropy in soft magnetic films for synthetic spin valves
|
Chang, H. W.; Yuan, F. T.; Lin, D. Y.; Tseng, D. H.; Chang, W. C.; Chen, Y. S.; Lin, J. G. |
| 臺大學術典藏 |
2021-09-02T00:05:16Z |
5G radio access network design with the fog paradigm: Confluence of communications and computing
|
Ku Y.-J;Lin D.-Y;Lee C.-F;Hsieh P.-J;Wei H.-Y;Chou C.-T;Pang A.-C.; Ku Y.-J; Lin D.-Y; Lee C.-F; Hsieh P.-J; Wei H.-Y; Chou C.-T; Pang A.-C.; HUNG-YU WEI |
| 臺大學術典藏 |
2021-09-01T01:53:43Z |
Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
|
ANN-LII CHENG; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E. |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
|
Yen C.-J.; Kim T.-Y.; Feng Y.-H.; Chao Y.; Lin D.-Y.; Ryoo B.-Y.; Huang D.C.-L.; Schnell D.; Hocke J.; Loemb? A.-B.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-07-03T03:34:53Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:34:30Z |
Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection
|
Chen L.-T.; Chen M.-F.; Li L.-A.; Lee P.-H.; Jeng L.-B.; Lin D.-Y.; Wu C.-C.; Mok K.-T.; Chen C.-L.; Lee W.-C.; Chau G.-Y.; Chen Y.-S.; Lui W.-Y.; Hsiao C.-F.; Whang-Peng J.; PEI-JER CHEN |
